Literature DB >> 10731610

Hydroxyurea inhibits intracellular Toxoplasma gondii multiplication.

E J de Melo1, R O Mayerhoffer, W de Souza.   

Abstract

Tachyzoites of Toxoplasma gondii multiply within the parasitophorous vacuole (PV) until the lysis of the host cell. This study was undertaken to evaluate the effect of hydroxyurea (a specific drug that arrests cell division at G1/S phase) on the multiplication of T. gondii tachyzoites in infected Vero cells. Infected host cells were treated with hydroxyurea for periods varying from 5 to 48 h, and the survival and morphology of the parasite were determined. Hydroxyurea arrested intracellular T. gondii multiplication in all periods tested. After 48 h of incubation with hydroxyurea, intracellular parasites were not easily observed in Vero cells. Ultrastructural observations showed that infected host cells treated with hydroxyurea for 24 h or more presented disrupted intracellular parasites within the PV. However, the host cells exhibited a normal morphology. Our observations suggest that hydroxyurea was able to interfere with the cycle of the intracellular parasite, leading to the complete destruction of the T. gondii without affecting the host cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731610     DOI: 10.1016/s0378-1097(00)00074-4

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  6 in total

1.  Efficient growth inhibition of Bacillus anthracis by knocking out the ribonucleotide reductase tyrosyl radical.

Authors:  Eduard Torrents; Margareta Sahlin; Daniele Biglino; Astrid Gräslund; Britt-Marie Sjöberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-01       Impact factor: 11.205

2.  Inhibition of Toxoplasma gondii growth by pyrrolidine dithiocarbamate is cell cycle specific and leads to population synchronization.

Authors:  Magnolia M Conde de Felipe; Margaret M Lehmann; Maria E Jerome; Michael W White
Journal:  Mol Biochem Parasitol       Date:  2007-09-21       Impact factor: 1.759

Review 3.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

4.  Evaluation of ATM Kinase Inhibitor KU-55933 as Potential Anti-Toxoplasma gondii Agent.

Authors:  Jonathan Munera López; Agustina Ganuza; Silvina S Bogado; Daniela Muñoz; Diego M Ruiz; William J Sullivan; Laura Vanagas; Sergio O Angel
Journal:  Front Cell Infect Microbiol       Date:  2019-02-13       Impact factor: 5.293

5.  A Perspective on Thiazolidinone Scaffold Development as a New Therapeutic Strategy for Toxoplasmosis.

Authors:  Cristian Rocha-Roa; Diego Molina; Néstor Cardona
Journal:  Front Cell Infect Microbiol       Date:  2018-10-16       Impact factor: 5.293

Review 6.  Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs.

Authors:  Sergio O Angel; Laura Vanagas; Diego M Ruiz; Constanza Cristaldi; Ana M Saldarriaga Cartagena; William J Sullivan
Journal:  Front Cell Infect Microbiol       Date:  2020-06-12       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.